L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the prophylactic effect of exogenous L-CARNOSINE in Oxaliplatin induced peripheral neuropathy, Thus half of the patients will receive L-CARNOSINE with Oxaliplatin and the other half will not receive L-CARNOSINE with their chemotherapy (oxaliplatin),And then neuropathy together with some oxidative stress markers will be assessed at the end of treatment duration (three months) .

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Collaborators: Ain Shams University; Misr International University
• Treatments: Oxaliplatin

Criteria

Inclusion Criteria:

Patients are eligible to be enrolled in this study, if they meet the following criteria

1. Elderly males and females with age (˃18 and ˂60).

2. Cancer patients treated with oxaliplatin for the first time (dose 85- 135mg/m2) administered every two to three weeks for 3 months.

Exclusion Criteria:

Excluded from this study are the patients with the following Criteria:

• Suffering from diabetes mellitus.

• Suffering from peripheral neuropathy as a result of any other disease or drug.

• Suffering from severe renal impairment (CrCl ˂ 30 ml/min).

• Suffering from epilepsy.

• Taking vitamin B.

• Who previously took Oxaliplatin or any other chemotherapeutic agent that causes peripheral neuropathy.

• Taking antidepressants or MAOI's.

• Taking NSAIDs, paracetamol, opiates or any other analgesics or pain killers.

• Pregnant or lactating patients.